CV Sciences (CVSI) Capital Expenditures Growth (1y) (2014 - 2026)
CV Sciences (CVSI) Capital Expenditures Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.95 Bn | 88.09 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.88 Bn | 32.14 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.64 Bn | 30.70 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 23.04 Bn | 20.88 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.37 Bn | 18.57 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.45 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | -21.54% |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | -92.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.50% |
| Dec 31, 2025 | -50.00% |
| Mar 31, 2021 | -53.95% |
| Dec 31, 2020 | -27.35% |
| Sep 30, 2020 | -820.69% |
| Jun 30, 2020 | 760.00% |
| Dec 31, 2019 | 26.09% |
| Jun 30, 2019 | 136.23% |
| Dec 31, 2018 | 99.51% |
| Jun 30, 2018 | -2,252.89% |
| Sep 30, 2016 | 1,720,600.00% |
| Dec 31, 2015 | -76.80% |
| Sep 30, 2015 | -100.00% |
| Jun 30, 2015 | -92.53% |
| Mar 31, 2015 | 703.64% |
| Dec 31, 2014 | 299.53% |
| Sep 30, 2014 | -27.30% |
| Jun 30, 2014 | 1,101.41% |